Medicare Spending on New Alzheimer’s Drugs Falls Short of Billion‑Dollar Forecasts

Why It Matters

The gap between projected and actual Medicare spending on Leqembi and Kisunla highlights the difficulty of translating breakthrough drug approvals into widespread clinical use. It forces insurers, manufacturers, and regulators to confront the reality that high‑priced, complex therapies may not deliver the cost‑effectiveness that early models assumed. For the broader healthcare system, the episode serves as a cautionary tale about relying on optimistic sales forecasts when budgeting for novel, high‑cost treatments. Moreover, the shortfall has political ramifications. Federal lawmakers have been scrutinizing the rising cost of specialty drugs, and the Medicare experience with Alzheimer’s therapies could shape future legislative proposals on drug pricing, coverage criteria, and value‑based reimbursement models. The outcome will influence how quickly future disease‑modifying agents reach patients and how much the government is willing to allocate toward them.

Key Takeaways

• CMS says Medicare will not spend billions on Leqembi and Kisunla in 2026‑27, a sharp downgrade from earlier forecasts.
• Uptake is low because both drugs require IV infusions, extensive imaging, and have limited eligible patient pools.
• Initial projections anticipated billions in annual Medicare outlays on Leqembi alone.
• Modest cognitive benefits and risk of brain bleeding have tempered prescriber enthusiasm.
• The spending gap eases federal budget pressure but raises concerns about patient access to the only disease‑modifying Alzheimer’s options.

Pulse Analysis

The Medicare shortfall on Alzheimer’s drugs underscores a broader pattern where high‑priced, disease‑modifying therapies struggle to achieve market penetration once real‑world complexities surface. Early revenue models often assume idealized patient adherence and streamlined delivery, but the intravenous administration and imaging requirements of Leqembi and Kisunla create friction points that erode uptake. This friction is amplified by a narrow eligibility window—most patients with early‑stage Alzheimer’s do not meet the strict criteria, and many clinicians remain skeptical of the modest cognitive gains relative to the risk profile.

From a fiscal perspective, the unexpected savings for Medicare are a double‑edged sword. While the program avoids the projected billions in drug spend, the savings come at the cost of limited patient access to the only therapies that claim to alter disease progression. Policymakers may interpret the data as evidence that aggressive pricing for breakthrough drugs is unsustainable, potentially spurring tighter coverage rules or stronger price‑negotiation authority for Medicare. Conversely, manufacturers might double down on developing more convenient delivery mechanisms—subcutaneous injections or oral formulations—to overcome the logistical barriers that have hamstrung current uptake.

Looking forward, the episode could accelerate the shift toward value‑based contracts in the specialty drug arena. If Medicare ties reimbursement to measurable outcomes such as slowed cognitive decline or reduced hospitalization, manufacturers will have a stronger incentive to demonstrate real‑world efficacy. The current situation also raises a strategic question for biotech firms: should they prioritize rapid regulatory approval or invest more heavily in post‑approval implementation support? The answer will likely shape the next wave of Alzheimer’s therapeutics and determine whether future breakthroughs translate into meaningful, fiscally responsible patient care.